Valuation: Pluristem Therapeutics

Market Cap 1.25Cr 1.11Cr 1.03Cr 93.21L 1.74Cr 118.36Cr 1.77Cr 12Cr 4.9Cr 62Cr 4.68Cr 4.58Cr 195.51Cr P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 3.96Cr 3.53Cr 3.27Cr 2.96Cr 5.54Cr 375.71Cr 5.63Cr 39Cr 16Cr 196.85Cr 15Cr 15Cr 620.61Cr EV / Sales 2025
3,90,78,124x
EV / Sales 2026 4,89,16,935x
Free-Float
57.48%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 54 01/02/2015
Director/Board Member 56 06/01/2021
Director/Board Member 64 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 1.3Cr
+2.41%-6.33%+43.43%+71.02% 6.33TCr
-0.15%+7.50%+11.01%+73.48% 5.49TCr
+0.57%+4.60%+10.07%+92.86% 5.33TCr
+0.37%+4.67%+27.03%+52.07% 4.58TCr
-1.21%+2.32%+21.80%+123.81% 4.35TCr
-0.37%+5.07%+249.91%+918.74% 4.02TCr
+0.05%+6.75%+14.48%+56.75% 3.35TCr
+1.19%-5.84%+27.86%-0.65% 2.37TCr
-0.38%+5.68%+36.43%+27.54% 2.38TCr
Average +0.59%+0.33%+49.11%+157.29% 4.24TCr
Weighted average by Cap. +0.38%+0.55%+47.50%+159.05%

Financials

2025 2026
Net sales 1.34 1.19 1.1 1 1.87 126.83 1.9 13.26 5.25 66.45 5.01 4.91 209.49 1.02 0.91 0.84 0.76 1.42 96.45 1.44 10.09 3.99 50.53 3.81 3.73 159.31
Net income -2.26Cr -2.02Cr -1.86Cr -1.69Cr -3.16Cr -214.38Cr -3.21Cr -22Cr -8.88Cr -112.32Cr -8.48Cr -8.29Cr -354.11Cr -2.38Cr -2.13Cr -1.97Cr -1.78Cr -3.33Cr -226.13Cr -3.39Cr -24Cr -9.36Cr -118.48Cr -8.94Cr -8.75Cr -373.53Cr
Net Debt 1.34Cr 1.2Cr 1.11Cr 1Cr 1.88Cr 127.56Cr 1.91Cr 13Cr 5.28Cr 67Cr 5.04Cr 4.94Cr 210.7Cr 2.71Cr 2.42Cr 2.24Cr 2.03Cr 3.79Cr 257.35Cr 3.85Cr 27Cr 11Cr 134.84Cr 10Cr 9.96Cr 425.1Cr
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-